

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.-27. (Canceled)

28. (New) A method for treating a human patient suffering from inoperable tumors comprising:

1) administering to said patient biodegradable microspheres suspended in a sterile solution containing between 1.0 and 1.5% by weight/volume of a viscosity modifier; between 0.5 and 1.5% of a surfactant; and between 3.5 and 4.5% of an isotonicity agent, said microspheres releasing 5-FU, by stereotactic injection directly into the tumor, into the peritumoral area, or at the same time into both the tumor and the peritumoral area.

29. (New) Method according to claim 28, wherein the suspension contains 3 ml of the sterile solution, and between 700 to 800 mg of biodegradable microspheres.

30. (New) A method according to claim 28, wherein the viscosity modifier is sodium carboxymethylcellulose, the surfactant is polysorbate, and the isotonicity agent is mannitol.

31. (New) A method according to claim 29, wherein the viscosity modifier is sodium carboxymethylcellulose, the surfactant is polysorbate, and the isotonicity agent is mannitol.

32. (New) A method of treatment according to claim 28, wherein the amount of 5-FU is between 50 and 200 mg.

33. (New) A method of treatment according to claim 28, wherein the microspheres are administered by one or more repeated stereotactic injections.

34. (New) A method of treatment according to claim 28, wherein the biodegradable microspheres are coated with a polymer that delays the release of 5-FU and maintains in the parenchymal space a therapeutically effective concentration of 5-FU for a period of at least four weeks.

35. (New) A method of treatment according to claim 28, wherein the inoperable tumors are deep tumors or tumors located in functional zones.

36. (New) A method of treatment according to claim 35, wherein the inoperable tumors are brain tumors selected from the group consisting of glioblastomas, tumors of oto-rhinolaryngologic sphere, rectal tumors, osseous, hepatic, or brain metastasis, and non malignant cystic tumors.

37. (New) A method of treatment according to claim 36, wherein the inoperable tumors are craniopharyngiomas.

38. (New) A method of treatment according to claim 36, wherein the tumor is a brain tumor.

39. (New) A method of treatment according to claim 38, wherein the brain tumor is selected from the group consisting of glioblastomas, metastasis, and non malignant cystic tumors.

40. (New) A method of treatment according to claim 28, wherein the 5-FU further comprises a neuroprotective compound.

41. (New) A method of treatment according to claim 28, further comprising administering radiotherapy to said patient.